Novel Bispecific Antibody Drug IVONESCIMAB AKESO Shows Significant Efficacy In Multiple Solid Tumors
Guangzhou, China, October 15, 2023 – Ivonescimab Akeso (Kangfang Bio, HKEX: 9926.HK) today announced the…
News
TECVAYLI™ Approval Brings New Options For Multiple Myeloma Treatment
In October 2022, the U.S. Food and Drug Administration (FDA) granted accelerated TECVAYLI™ (teclistamab-cqyv) FDA…
What You Need to Know About Sulbactam-Durlobactam: Mechanism, Benefits, and FDA Approval
What is Sulbactam-Durlobactam? Sulbactam Durlobactam is a new and special drug combination used to combat…
Vonvendi Approved By FDA, Bringing New Hope For Patients With Type A Hemophilia
About Vonvendi Vonvendi (vonicog alfa) is a recombinant von Willebrand factor (VWF) developed by Baxalta.…
Enlonstobart Injection Bringing New Hope To Patients With Rare Diseases
On October 15, 2023, the U.S. Food and Drug Administration (FDA) officially approved Enlonstobart Injection…
FDA Approves Besremi (Ropeginterferon Alfa-2b) For The Treatment Of True Erythrocytosis
The U.S. Food and Drug Administration (FDA) recently announced the approval of Besremi (generic name:…
Bimekizumab Bimzelx: Expanding Approvals Highlight Its Efficacy Across Multiple Indications
UCB has recently announced that its innovative therapy, Bimzelx (generic name: bimekizumab-bkzx), has received approval…
Nuwiq Demonstrates Low Inhibitor Development Rates In Previously Untreated Patients With Severe Hemophilia A
Lachen, Switzerland – Octapharma has announced that the final results from the NuProtect study on…
Benralizumab Injection: A Breakthrough In Asthma And EGPA Treatment
In the world of immunology and asthma management, Benralizumab Injection has emerged as a game-changer…
Gamifant Emapalumab LZSG: Targeted Therapy For Primary Hemophagocytic Lymphohistiocytosis
The trade name of emapalumab lzsg is Gamifant, which is an anti interferon gamma (IFN…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights